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Palavras-chave:  Bactérias Gram-negativas, Infecções do Trato Urinário, β-
lactamase, AmpC 
 
Resumo:   As bactérias multirresistentes são um problema emergente 
por todo o mundo, associado a estadias prolongadas nos 
hospitais, e ao inerente aumento de custos. As bactérias 
produtoras de β-lactamases de espectro alargado, amplamente 
estudadas, e as produtoras de enzimas AmpC, não tão 
mencionadas, são objecto de grande importância, e a sua 
epidemiologia deve ser seguida de perto. 
  A epidemiologia de bactérias produtoras de β-lactamases de 
espectro alargado de pacientes com mais de 65 anos que 
recorrem à Urgência com diagnóstico de infecção urinária, bem 
como a epidemiologia de estirpes produtoras de AmpC, foram 
avaliadas através do processo de identificação automática 
Vitek2®. Para os isolados AmpC positivos, testes fenotípicos 
confirmatórios foram usados para detectar a presença de enzimas 
AmpC. 
  Os valores elevados de isolados produtores de β-lactamases 
de espectro alargado detectados em pacientes com infecção 
urinária e mais de 65 anos são o maior motivo de preocupação. 
Uma vez que estes recorrem frequentemente à Urgência ou vivem 
em lares, estes doentes são potenciais veículos de transmissão 
destas bactérias multirresistentes. Um problema que estava 
confinado ao ambiente hospitalar é, hoje em dia, foco de atenção 
por se encontrar espalhado por toda a comunidade.  
   Quanto às bactérias produtoras de AmpC, embora sejam 
menos frequentes do que as produtoras de β-lactamases de 
espectro alargado, a sua presença pode mascarar a presença do 
fenótipo característico destas. A avaliação incorrecta induz à 
prescrição errada de medicamentos e ao consequente surgimento 
x 
 
de estirpes resistentes. Para além disso, existe a possibilidade de 
se detectarem ambos os mecanismos de resistência na mesma 
estirpe, aumentando a necessidade de se usarem métodos 
complementares que as distingam, uma vez que o método 
automático não é capaz de o fazer. O disco de Cefoxitina é o teste 
indicado para complementar a identificação da presença da 
enzima AmpC. 
  Este estudo mostra a importância de estudar a epidemiologia 
das β-lactamases, e fornece uma visão realista da sua 
disseminação pela comunidade, bem como das suas implicações 
no sistema de saúde da região de Aveiro.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key words:  Gram-negative bacteria, Urinary Tract Infections, β-lactamase, 
AmpC 
 
Abstract:   Multidrug resistant bacteria are an emerging problem 
worldwide, associated with prolonged stays in the hospital and 
inherent increased costs. Widely studied ESBL-producers, and the 
not so considered AmpC-producers are of extreme importance, 
and its epidemiology should be closely followed.  
  The epidemiology of ESBL-producing isolates from patients 
over 65 attending the ER and diagnosed with a UTI, as well as the 
epidemiology of AmpC-producing isolates were assessed by the 
Vitek2® procedure of identification. For the AmpC positive 
isolates, confirmatory phenotypic test were performed, searching 
for the presence of an AmpC enzyme.  
High numbers of ESBL-producing isolates, detected in UTI 
patients over 65 years old are the main motive of concern, since 
these are recurrent visitors of hospitals and frequently live in 
nursing homes, which makes them potential carriers of 
multiresistant strains. The earlier hospital restricted problem has 
now become widely spread in the community, and requires further 
attention. 
As for the AmpC, although less frequent than ESBLs, its 
presence often masks the ESBL phenotype. Misevaluation and 
false reports induces wrong medication procedures and the 
consequent emergence of selected resistant strains. Also, the 
possibility of identifying both resistance mechanisms in one 
organism has become more common, rising the need of 
complementary methods to distinguish them, which the automated 
method is unable to do. Cefoxitin disc was found to be the right 
complementary test to perform in order to detect these kinds of 
multiresistant strains. 
xii 
 
This study shows the importance of following the epidemiology 
of β-lactamases, providing a realistic view on its dissemination 
trough the community and its implications in the health care 
system in our region. 
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1.1 General context 
Infections caused by multidrug resistant bacteria are rapidly emerging and 
are responsible for a worldwide increase of health care-associated costs. 
Multidrug resistant bacteria can include Gram-negative strains expressing 
extended spectrum β-lactamases (ESBL), carbapenemases such as Klebsiella 
pneumoniae carbapenemase (KPC) and/or Enterobacteriaceae expressing 
chromosomal AmpC beta-lactamases (cAmpC). (Conen, Frei et al. 2015) The 
latter isolates are not yet as well studied as other isolates expressing ESBL are, 
which is disturbing since they are equally a major setback in the treatment of this 
kind of infections. (Maraskolhe, Deotale et al. 2014) 
 
Several studies report that prolonged stays at the hospital usually leads to 
infections caused by ESBL producers, and thus reduced rates of clinical response 
to antimicrobial treatments. (Conen, Frei et al. 2015) Therefore, a more accurate 
clinical profile of the risk population would be useful in defining strategies to apply 
to this subset of patients, regarding future savings both in costs and in mortality 
rates. 
 
One of the most important and most used classes of antibiotics are the        
β-lactams. Consequently, without surprise, they are plagued with problems of 
resistance, and the development of new antibiotics (derived by side chain 
alterations) is not keeping pace with the resistance development. (Worthington 
and Melander 2013) 
 
For all the exposed above, the epidemiology of ESBL producing isolates in 
patients attending the emergency room (ER), diagnosed with an urinary tract 
infection (UTI) and older than 65 years old and the epidemiology of AmpC 
producing isolates causing infections, in Centro Hospitalar do Baixo Vouga 
(CHBV) was the focus of this study.  
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1.2. Bacterial isolates  
Each and everyone of us carries 10 times more bacterial cells than human 
body cells. Despite their vast number, bacteria do not occupy that much space 
since their size is much smaller than human cells. For a long time, scientists 
believed that these bacteria, despite their numbers, would do us neither much 
harm nor much good. (NIH 2012) 
 
However, lately several studies have been shown that bacteria are very 
important for us, for instance, in maintaining our immune system healthy and by 
producing chemicals that help us harness energy and nutrients. On the other 
hand, with the improvement on life conditions, we tend to live longer, which results 
in an increase of exposition to antibiotherapy through our lives and consequently 
some of the bacteria we carry can become multiresistant. If most of the time this 
situation pose no problem, in the right conditions, from the bacteria point of view, it 
can be fatal to the human being. (Bermon, Petriz et al. 2015) 
 
We tend to forget that bacteria have inhabited the planet for approximately 
three and a half billion years, longer than mankind, and that they had to adapt on 
innumerable occasions to toxic substances suddenly introduced into their 
environments. (Bennett 2008) The systematic development of resistance 
mechanisms to the antibiotherapy was only one of those adaptations, that have 
been passed over time as a result of the effect of antibiotherapy selective 
pressure. 
 
 
1.2.1. Enterobacteriaceae 
One of the most common member of the Enterobacteriaceae family, is 
Escherichia coli, also the main aerobic commensal bacterial species in the bowel 
flora yet, in the urinary tract or in blood, it can become pathogenic. In fact, it is the 
leading Gram-negative pathogen causing nosocomial and community acquired 
infections. Since E. coli easily acquires resistance and is commonly found in many 
different animal species, its antimicrobial resistance profile is well documented 
worldwide. (von Baum and Marre 2005; Erb, Sturmer et al. 2007) It is frequently 
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resistant to aminopenicillins, such as amoxicillin or ampicillin and narrow-spectrum 
cephalosporins. (Tenover 2006) 
 
Multiresistant isolates of Enterobacteriaceae are becoming a common 
presence within the clinical environments, mainly because bacteria have an 
impressive capacity to acquire new genes and to rearrange its genetic information 
(Toleman, Bennett et al. 2006) In general, Enterobacteriaceae express low levels 
of AmpC, but this type of resistance is inducible in response to β-lactams 
exposure. (Jacoby 2009) 
 
Still, carbapenems (such as imipenem, meropenem and ertapenem) are the 
most active compounds against ESBL-producing strains of Enterobacteriaceae 
family. Among the most susceptible targets, E. coli, Klebsiella spp. and Proteus 
mirabilis represent about 98% of these strains, making carbapenems the preferred 
treatment for infections caused by these bacteria. 
 
However, strains of Enterobacteriaceae carrying KPC enzymes, which can 
render carbapenems uneffective, are emerging in the hospital environment. This 
situation lead colistin, once been considered toxic, to be taken as a last resort 
agent for multidrug resistant caused infections. (Perez, Endimiani et al. 2007) 
 
 
1.2.2 Other than Enterobacteriaceae agents 
Although Gram-negative bacteria are responsible for almost 70% of all 
urinary tract infections (Velez Echeverri, Serna-Higuita et al. 2014; Sultan, Rizvi et 
al. 2015) and Enterobacteriaceae are among the most common agents, 
Staphylococcus aureus, Pseudomonas aeruginosa and Enterococcus species are 
also frequently found as urine pathogens.  
 
Gram-negative organisms are the focus of most of the resistance studies, but 
equally dangerous are the emerging types of resistance mechanisms found in 
Gram-positive bacteria. Also, there is another type of pathogen capable of causing 
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UTIs, Candida yeast. Their potential as a urinary tract pathogen is dependent of 
successful colonization of body sites close to the urinary tract. C. albicans is 
considered normal flora of the body flora and is found in 15%–60% of the 
population. Candida species are unusual causes of urinary tract infections in 
healthy individuals, but fairly common in inpatients or among patients with 
predisposing diseases and structural abnormalities of the kidney and collecting 
system. (Fisher, Kavanagh et al. 2011) 
 
 
1.3. Infections caused by multidrug resistant bacteria 
 The innovative introduction of penicillin in the early 1940s was expected to 
mark the end of infectious diseases, but soon was realized that this was not going 
to be the case. The emergence of resistant strains was reported just a few years 
after its use and, since then, resistance to other classes of antibiotics was reported 
worldwide, mostly due to its overuse.  
 
Although the availability, the controlled and correct use of antimicrobials in 
developed countries has reduced morbidity and mortality, in developing countries 
they are empirically applied. The lack of laboratorial results to guide therapy and 
little information on susceptibility patterns results in many infectious diseases, 
once easily curable, to become untreatable. (Mshana, Matee et al. 2013) 
 
 
1.3.1. Urinary Tract Infections  
Urinary tract infections are one of the most common causes of hospitalization 
of patients coming to the emergency room, but also in inpatients. Symptoms of a 
lower UTI include dysuria without fever, chills or back pain, whereas upper UTI is 
often suggested by pyelonephritis, loin pain, flank tenderness, fever or other kind 
of inflammatory response. (Pallett and Hand 2010) 
 
Usually UTI are more frequent in women since the anatomy of the urinary 
tract in women has some characteristics that may promote it, namely, a longer 
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urethra and also the proximity to the periurethral region. In elderly, the risk of 
complicated UTIs is higher in case of prostatic disease in men or post-menopausal 
women, and thus, those who have higher possibility of developing antimicrobial 
resistances. Prolonged stays in the hospital, serious complications and extended 
periods of antibiotic consumption are amongst the main risk factors. (Pallett and 
Hand 2010)  
 
The choice of agents to treat these infections is now focused on 
combinations of antibiotics, and broad spectrum agents, such as carbapenems, 
are being used increasingly as empirical treatment for severe infections, leading to 
the emergence of organisms producing carbapenemases. Because this kind of 
resistance is becoming more widespread, it is critical that antimicrobial agents are 
carefully used as prophylaxis or in asymptomatic bacteriuria. (Pallett and Hand 
2010) The antimicrobial oral options for the treatment of complicated UTI caused 
by ESBL or AmpC producing strains are now limited, especially because of current 
resistance to trimethoprim and quinolones. The rest of these bacteria remain 
susceptible to nitrofurantoin (for lower UTIs) and fosfomycin. (Pallett and Hand 
2010) 
 
E. coli is one of the most common organisms causing UTIs in the community, 
and because multidrug resistant strains are more and more frequent, old 
treatments are struggling to be effective against these emerging UTIs. Other 
Gram-negative microorganisms, such as urease positive organisms, namely 
Proteus spp, Morganella morgannii, Providencia stuartii and Pseudomonas 
aeruginosa are frequently found in indwelling devices, and are also leading causes 
of UTIs. The resistance developed by these Gram-negative species, especially 
those that produce AmpC enzymes or extended spectrum β-lactamase (ESBL) 
poses a major problem in the treatment of these infections. Enterobacter cloacae, 
for example, expresses a chromosomal AmpC β-lactamase that render most of the 
β-lactams uneffective. Also, Gram-positive cocci, such as methicillin-resistant 
Staphylococcus aureus (MRSA) or Staphylococcus saprophyticus, are described 
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as species causing UTIs. Responsible for about 5% of all UTIs is another frequent 
colonizing organism Candida albicans. 
 
 
1.3.2. Skin and soft tissue infections (SSTIs) 
Being the largest organ of the human body and together with the underlying 
soft tissue (which includes the fat layers, fascia and muscle), skin represents the 
majority of all tissue in the body. Skin plays an important role in humans’ health: it 
acts as a tough, flexible and structural barrier to invasion. It is usually colonized 
with a normal flora, which acts as a competitive inhibitor of pathogenic 
microorganisms.  
 
Once this barrier is broken or injured, by leg ulcers, burns, surgical or 
traumatic wounds, it allows colonization by a broad range of bacteria. Although 
colonization does not require antibiotherapy, infection might, and systemic 
antibiotics are often used to manage methicillin-resistant Staphylococcus aureus 
(MRSA). MRSA are the major infection agent causing skin and soft tissue 
infections, as well as β-hemolytic streptococci, usually Lancefield groups A, C and 
G, with group B occurring in diabetics and in elderly. (Dryden 2010; Mendes and 
Neves 2012) 
 
Localized pus-producing lesions such as abscesses, carbuncles or wound 
sepsis are usually staphylococcal, while β-hemolytic streptococci are often 
responsible for spread infection such as erysipelas or cellulitis. When deeper 
vascular tissue is compromised, as in diabetic foot or ischemic ulcers, 
polymicrobial infections may occur, involving both Gram-positive and 
Enterobacteriaceae. Pseudomonas aeruginosa is specifically associated with 
wounds treated with wet bandages. (Dryden 2010) 
 
In chronic patients, with diabetic foot, for example, previously submitted to 
treatment with antibiotics, infection is likely to be polymicrobial, and require broad-
spectrum antibiotic treatment. (Mendes and Neves 2012)  
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1.4. Antibiotics 
 
The first observation of a bacterial inhibitor was made in early 20th century, 
when Paul Ehrlich, a German physician, found that an arsenic derived compound, 
salvarsan, could treat syphilis without harming the patient, as arsenic would do. 
The Nobel Price in 1908 recognized its importance, and about 30 years later, 
investigators Domagk and Tréfouël conducted experiments based in this finding 
that would lead to the discovery of sulphonamides. 
 
In 1928, an accidental finding by Alexander Fleming led to the use of 
penicillin as the first and major antibiotic in the times to come. While coming back 
from holidays to his studies on Staphylococcus aureus, he realized that the 
cultures he had forgotten in the bench have been killed by a colony of 
contaminating Pennicillium. The bactericidal effect of penicillin and non toxicity to 
human made it the most successfully employed antibiotic in the Second World 
War, and was the first choice against Gram-positive organisms while no resistance 
was developed. 
 
If the first antimicrobial substances were only produced by fungi and bacteria, 
nowadays they can be artificially synthesized in pharmaceutical laboratories. An 
antimicrobial agent is a substance, naturally or artificially obtained, with the 
capability of killing or inhibiting microorganism growth, active against bacteria, 
fungi and parasites. The ideal antibiotic should produce this effect with a small 
amount, with no toxic or collateral effects for the human host. 
 
Antibiotics can be divided according to their biological origin, chemical 
structure, but also according to the effect on the pathogens. Mainly, they are 
divided in bacteriostatic – if they can only inhibit microbial growth – or bactericidal 
– if they kill part of the population, then associated with a minimal inhibitory 
concentration (MIC).  
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According to the targeted vital region of the pathogens’ cell, antibiotics may 
also be divided into five categories (Figure 1): cell wall synthesis, protein 
synthesis, ribonucleic acid (RNA) synthesis deoxyribonucleic acid synthesis (DNA) 
and intermediary metabolism. (Hooper 2001; Clatworthy, Pierson et al. 2007) 
 
 
 
 
 
 
Figure 1 - Traditional targets of antibacterial compounds on the cell vital 
mechanisms 
 
 
Exposure to antimicrobial agents has soon produced resistant strains, and 
efforts to produce new and more efficient ones are an everyday struggle in 
science. Bacteria can mutate as quickly as new agents are discovered, and that is 
shown in Figure 2, a timeline of antibiotic deployment and the evolution of 
antibiotic resistance. 
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Figure 2 - Timeline of antibiotic deployment and the evolution of antibiotic 
resistance. (Clatworthy, Pierson et al. 2007) 
 
 
The overuse of antibiotics has lead to the appearance of resistant bacteria, 
often the result of extensive selective pressure. Different mechanisms were 
developed by bacteria in order to escape new and improved antimicrobial agents: 
 β-lactamase or penicillinase enzymes production, which act on the     β-
lactam ring, inactivating or destroying the antibiotic molecule; 
 Incapacity of the antibiotic to break into the bacterial cell; 
 Target alterations on the molecular basis, changing the inhibited 
metabolic pathway to an alternatively efficient one; 
 Efflux pumps that reject the antibiotic before it can be effective.  
 
The first line antibiotics used in hospital, like cephalosporins, are now being 
threatened by the emergence of resistance mechanisms like ESBLs. And the main 
challenge is now the rapid identification of the exact kind of resistance, in order to 
quickly apply the correct medication and avoid the increasing morbidity and 
mortality rates. These kind of strains often presents multidrug resistance, being 
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also resistant to amino-glycosides and fluoroquinolones, and thus reducing the 
therapeutic options for those severe infections. (Ghafourian, Sadeghifard et al. 
2014) 
 
 
1.4.1. β-lactams 
For the past 60 years the β-lactams have been the most successful drug in 
the treatment of bacterial infections, for both Gram-positive and Gram-negative. In 
2004, they represented over 65% of the worlds’ antimicrobial market. Not 
surprisingly, the increased use of penicillins caused resistance to arise in the 
clinical setting. Penicillin G was the first β-lactam antibiotic to be introduced in 
clinic practice, in the early 1940s, and by 1944, the first reports of penicillin-
resistant Staphylococcus aureus began to emerge. These were the first references 
to β-lactamase enzyme production, that inactivate the antibiotic molecule by 
hydrolyzing the β-lactam core. β-lactams act by mimicking the natural substrate of 
the Penicillin-Binding-Proteins (PBP) – D-Ala-D-Ala – which is responsible for 
cross-linking the peptidoglican section of the cell wall. By forming this complex, 
they inhibit the transpeptidation activity and disrupt the integrity of the cell wall, 
ultimately resulting in cell lysis. (Bush 2010; Bush and Jacoby 2010; Worthington 
and Melander 2013) 
Non-β-lactams are usually useless against ESBL producers, because 
plasmids that carry the ESBL gene also carry genes encoding resistance to other 
classes of antibiotics, such as quinolones, aminoglycosides, and tripethoprim-
sulfamethoxazole. (Delgado-Valverde, Sojo-Dorado et al. 2013) 
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Figure 3 - Structures of the different β-lactam antibiotic classes. (Worthington 
and Melander 2013) 
 
 
1.4.2 Mechanisms of resistance to β-lactams: β-lactamases 
To escape β-lactam antibiotics effects, Gram-negative bacteria have 
developed multiple strategies: production of β-lactamases, novel PBPs with 
reduced affinity to β-lactams, porin mutations that reduce β-lactam entry or 
multidrug efflux pump that expel β-lactams out of cell. Of these mechanisms, β-
lactamase production is still the most efficient. (Zeng and Lin 2013) 
 
 Clinically relevant β-lactamases include Extended Spectrum β-Lactamases 
(ESBL), AmpC β-lactamases, Klebsiella pneumoniae carbapenemases (KPC) and 
Metallo-β-lactamases. A combination of those can also be expressed, as well as 
nonenzyme resistance mechanisms, namely porin loss and efflux pumps. (Marsik 
and Nambiar 2011) 
 
β-lactamase enzymes can be classified according to Amblers’ molecular 
characterization system or the Bush functional classification scheme. The 
molecular classification is based on the amino acid sequence, and results in 4 
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groups of β-lactamases: A, B and D enzymes, which utilize serine for the 
hydrolytic activity, and class B metalloenzymes, which require divalent zinc ions to 
hydrolyze the substrate. As for the functional classification scheme, it has been 
updated from the original one, back in 1995, proposed by Bush et al., and it takes 
in consideration the substrate and inhibitor profiles of the enzyme, sorting them in 
close correlation with the phenotypic characteristics. (Bush and Jacoby 2010) 
 
 
 
1.5 Scope 
The main goal of this thesis is to contribute to the knowledge of distribution 
and prevalence of resistance in selected species collected within the hospital 
environment. Microorganisms were isolated from samples, collected at the Centro 
Hospitalar do Baixo Vouga, EPE in Aveiro. The study focuses on antibiotic 
resistance strains, in resistant and MDR isolates. Since the community 
environment also seems to be an important reservoir of antibiotic resistant 
microorganisms, isolates were collected from patients attending the emergency 
room and were assumed to represent the community. 
 
Being exposed the growing need for more accurate results, this thesis has 2 
main goals: 
 
a) the epidemiology of ESBL producing isolates in patients attending the 
emergency room (ER), diagnosed with an urinary tract infection (UTI) and older 
than 65 years old;  
 
b) the epidemiology of AmpC producing isolates, in Centro Hospitalar do 
Baixo Vouga (CHBV) 
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2.1. Central Hospital characterization 
The present work was performed in the section of Microbiology of the clinical 
pathology department, in the “Centro Hospitalar do Baixo Vouga, E.P.E. – Hospital 
Infante D. Pedro (HIP)”. HIP is one of the three units that compose the “Centro 
Hospitalar do Baixo Vouga (CHBV)” and includes several wards, namely internal 
medicine, general surgery, orthopedics, pediatrics, urology, infect logy, cardiology, 
pneumology, gynecology and obstetrics. 
The emergency room of this hospital also comprises several medical 
specialties, in which clinical pathology is included. 
 
 The tests performed in the Microbiology Laboratory are of utmost 
importance to an accurate diagnosis allowing the identification of the pathogen 
and its resistance and/or susceptibilities to the antibiotics available, thus being 
essential for the success of patient treatment.  
 
All the isolates used in this study were collected from both inpatients and 
patients attending the ER of “Centro Hospitalar do Baixo Vouga, E.P.E.”, from 
January to December 2014. 
 
 
2.2. Bacterial strains  
Isolates were collected according to the aim of each study (specified in 
chapters 1 and 2) 
After entering the Microbiology laboratory, the sample was cultured in the 
appropriate culture medium. Urine samples were inoculated in CLED (Cystein 
Lactose Electrolyte Deficient medium) (BioMérieux, France), and incubated at 
37ºC for 16 to 24 hours. If the culture presented 1x105 CFU/ml or more, it was 
considered a significant bacteriuria and, thus, proceeded to isolation of the 
potentially pathogenic microorganism. All other types of samples (pus, sputum, 
blood) were inoculated in other culture medium: once positive for the presence of 
microorganisms, colonies were passed to MacConkey Agar (selective and 
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differential medium with violet crystal) (BioMérieux, France), Columbia Agar (with 
5% sheep blood) (BioMérieux, France) or Chocolate Agar (obtained from 
Columbia Agar, by heating at 80ºC) (BioMérieux, France), depending on being 
Gram-negative bacilli or Gram-positive cocci, and if detection of hemolysis was 
needed. 
Plates were then incubated for 16 to 24 hours at 37ºC, so that identification 
could be performed. Additional assays like Gram staining and biochemical tests 
were also made, in order to facilitate the choice of the panel to be used in the 
automated method. 
 
Control strains were used as standard procedure in the Vitek2 system and 
also in the performance of phenotypic methods. The strains used were E.coli 
ATCC and Serratia marcescens as a negative and positive control for AmpC 
production. Three random E. coli reported as AmpC negative by the Vitek2® 
system were used to evaluate the specificity and sensitivity of both methods.  
 
2.3. Identification and susceptibility testing (automated method) 
Vitek2® (BioMérieux, France) is an automated system that allows the 
identification of the bacterial species and antibiotic susceptibility pattern of the 
microorganism in a 24 hour period. The system is based on an optic system 
combining a multichannel fluorometer and photometer, that register alterations in 
fluorescence, turbidity and color. (Figure 3, www.biomerieux.com) 
 
The identification was made from a pure and fresh culture, and taking in 
consideration the results of a set of 64 tests, each containing an individual 
substrate, evaluating the metabolic activity of the organism: acidification, 
alcalinization, enzymatic hydrolysis or growth in the presence of inhibitors. Both 
contamination and alteration in oxygen levels were assured by a transparent film 
on all the wells of the card. Each card contains a bar code, reporting the type of ID 
card, lot number, expiring date and the corresponding sample identification for the 
equipment. In order to comprise all microorganisms, there are four distinct cards 
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available: 1) Gram-negative bacilli, fermenter or non-fermenter; 2) Gram-positive 
cocci and non-spore former bacilli; 3) yeasts; 4) Gram-positive spore-former cocci. 
 
The fresh and pure culture was taken to a suspension of 0,5 to 0,63 
McFarland and inoculated, trough a vacuum system, into the chosen card. The 
cards were then incubated at 35,5±1ºC and read every 15 minutes. The results are 
compared with a database of well characterized strains, and an ID is obtained with 
a certain degree of similarity of metabolic test. 
According to CLSI criteria, the results are only acceptable when the 
equipment is verified by the quality control system. For that, reference strains are 
tested, E. coli ATCC 25922 and K. pneumonia ATCC 700603, and only then 
results are validated. 
 
 
 
Figure 4 - Vitek2® automated system schematic work flow 
(www.biomerieux.com) 
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In a similar methodology, Vitek2® is also capable of testing the susceptibility 
to a battery of antimicrobial agents, by comparing MIC patterns. The type of card 
is chosen according to the Gram staining, and can vary between AST-N222 and 
AST-N192 cards (for Gram-negatives), AST-619, AST-586 e AST- ST01 (for 
Gram-positives) and YST ID for yeasts. The results are expressed in sensitive, 
intermediate or resistant phenotype.  
 
 
2.4 Phenotypic methods 
  
2.4.1 Quantitative method Etest  
Strains identified by the automated system as ESBL producers were 
confirmed using phenotypic tests in order to detect the production of β-lactamases.  
A fresh and pure culture is taken to a suspension of 0,5 McFarland and spread 
into a Mueller Hinton Agar plate, in all directions, with a sterile swab. After being 
left to dry for five minutes, Etest strips (AB BioMérieux, Sweden) were placed on 
top of the medium.  
 
Each Etest strip to detect ESBL producers is divided in two regions: in one 
side, a crescent concentration gradient of one antibiotic, from the center to the top, 
and in the other side, the same antibiotic in association with a β-lactamase 
inhibitor. The strips contain a cephalosporin and an association of a cephalosporin 
with clavulanic acid as follows: cefotaxime and cefotaxime + 4 µg/ml clavulanic 
acid (CT/CTL), ceftazidime and ceftazidime + 4 µg/ml clavulanic acid (TZ/TZL) and 
cefepime and cefepime + 4 µg/ml clavulanic acid (PM/PML)  
 
The Etest strips used to detect ESBL producers were as explained in    
Figure 4. The plate was incubated for 24h, at 37ºC and the interpretation of the 
ellipses formed was interpreted.  
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Figure 5 - Configuration of Etest ESBL strips (www.abbiodisk.com) 
 
 
A positive result is obtained when the ratio between the value of the MIC 
obtained for the antibiotic alone and its association with an inhibitor, for example, 
CT/CTL, is higher than eight. On the other hand, if the result obtained is inferior to 
eight, the result is considered negative. If it is not possible to obtain a MIC value 
either for the antibiotic alone or the antibiotic in combination with the inhibitor the 
result is considered non determined.   
 
 
2.4.2 Cefoxitin disc test 
Since resistance to cefoxitin is a good indicator of the presence of plasmidic 
AmpC, cefoxitin disc test by diffusion in an agar plate was used to determine the 
susceptibility in all the isolates suspected to be an AmpC producer.  
A pure and fresh culture was used to prepare a 0,5 McFarland that was  
spread on a Mueller-Hinton agar plate, in all directions, with a sterile swab. A 
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cefoxitin disc (30µg) was placed on the surface and plate incubated at 35±2ºC for 
16-18h, in aerobic conditions. The result was read in the diameter of the inhibition 
zone: the microorganism is considered susceptible to cefoxitin if the inhibition 
diameter is larger than 18mm; cefoxitin resistant strains have 17mm or less of 
inhibition halo diameter and are, therefore, potentially AmpC producers.  
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3.1. Introduction 
 
The world population is getting older and therefore more prone to acquire 
infections than can lead to hospitalization, and in a more complicated scenario can 
cause severe morbidity and mortality. Among those infections, urinary tract 
infections (UTIs) are one of the most prevalent community-acquired infections. 
Patients with severe illnesses and/or hospitalized for long periods are the ones 
showing higher risk of being infected with ESBL producers because of the inherent 
use of large amounts of antibiotics. Among the hospital environment, transmission 
usually occurs by fecal-oral way, and is mostly related to hand contact between 
healthcare workers. (Ghafourian, Sadeghifard et al. 2014) 
 
Extended spectrum β-lactamases are capable of hydrolyzing various classes 
of β-lactam antibiotics: penicillins (e.g. ampicillin and piperacillin), cephalosporins 
of the first (cephalotin), second (cefuroxime), third (ceftazidime and cefotaxime) 
and fourth (cefepime) generations, and monobactams (aztreonam), but not 
carbapenems. Therefore ESBL producing strains are able to hydrolyze all the      
β-lactam antibiotics with high efficacy, except for carbapenems. (Livermore and 
Brown 2001) There are known and described more than 1000 distinct                   
β-lactamases. On the other hand, ESBLs can be inhibited by β-lactamase 
inhibitors like clavulanic acid, tazobactam or sulbactam. This phenotypic 
characteristic allows to distinguishing this kind of strains, except for the presence 
of a chromosomal AmpC, which makes them resistant to inactivation by a beta-
lactamase inhibitor. (Perez, Endimiani et al. 2007) Most ESBL mechanisms are 
mutational derivates of the classical TEM-1, TEM-2 and SHV-1 enzymes, resulting 
of one to four amino acid changes. These changings allow attack on 
aminothiazolyl cephalosporins and monobactams. (Livermore and Yuan 1996) 
  
Epidemiological studies, such as SMART (Study for Monitoring Antimicrobial 
Resistance Trends), concluded on the prevalence of cephalosporinases mediated 
by ESBL in E. coli (17,6%) and K. pneumonia (38,9%) in Europe; Significantly 
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lower were the results for the United States, 8,5% and 8,8%, respectively, and 
significantly higher, in Asia, with 40,8% for E. coli and  21,5% for K. pneumoniae. 
(Delgado-Valverde, Sojo-Dorado et al. 2013) 
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3.2. Results and Discussion   
 
3.2.1. Characterization of the collected samples 
 
A total of 1263 isolates were recovered during the timeframe of this study, 
January 2013 to December 2014, at Centro Hospitalar do Baixo Vouga, EPE, 
Portugal. The Centro Hospitalar do Baixo Vouga, EPE, comprises three hospitalar 
units, namely Hospital Infante D. Pedro, Hospital de Águeda and Hospital 
Visconde de Salreu. The population analyzed was non-repetitive and only single 
isolate/patient was included in the study. The isolates were selected according to 
the following criteria to each patient: primary diagnosed with an UTI, older than 65 
years old and attending to the ER. As the infection under study was an UTI, the 
biological product selected was urine. Figure 5 shows the distribution of the 
samples by the different methods used in sample collection, namely, midstream 
collection and civet (catheter). 
 
 
Figure 6 - Distribution of the samples by the different methods used in 
sample collection. 
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The majority of the samples was collected by the midstream method, 
nevertheless 14% of the samples were retrieved from civets. The use of civets in 
patients older than 65 years old, naturally increases since they can become more 
dependent. Despite the percentage of samples retrieved from civets being low this 
value requires vigilance, since the patients with civets are usually in higher risk of 
infection leading to an increase of hospitalization time.  
Figure 6 shows the analysis of the distribution of the samples collected by 
gender. It was observed, as expected, that 60% of the strains were isolated from 
urine samples retrieved from women, whereas 40% were retrieved from men. This 
result can be explained by the anatomic differences of the urinary system between 
men and women, which makes the UTIs more common in women than in men. On 
the other hand, in an era where women live longer than men it is expected to have 
women more represented than men. 
 
 
 
Figure 7 - Urinary tract infections distributed by gender; M- male, F- Female. 
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3.2.2. Characterization of the agents causing UTI 
 
As mentioned above the isolates were all collected from urine. Figure 8 
shows the general distribution of the isolates based in the Gram staining 
technique. It is shown that the vast majority of the isolates, 86%, were Gram-
negative, whereas the Gram-positive corresponded to 8% and yeast to 6%. These 
results are in accordance with the in the literature. 
 
 
 
Figure 8 - Distribution of the UTIs causing agents according to Gram staining. 
 
 
Also, it has been reported in previous studies that the most frequent bacteria 
isolated from urine, in patients with an UTI, belong to the Enterobacteriaceae 
family. In the present study similar results were obtained, as it can be observed in 
Figure 9. The samples analyzed showed a high phylogenetic diversity being 
Enterobacteriaceae the more represented family with 76% of the isolates, whereas 
other isolates than those belonging to the Enterobacteriaceae family represented 
24% of the total isolates.  
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Figure 9 - Classification of the agents causing UTIs. 
 
 
Among the Enterobacteriaceae family the most prevalent microorganisms 
isolated were E. coli (n=585), K. pneumoniae (n=203), Proteus mirabilis (n=82) as 
it is shown in Figure 10. Regarding the microorganisms classified as “Other than 
Enterobacteriaceae”, Enteroccocus spp, Pseudomonas aeruginosa and Candida 
spp, were the most common also isolated. The results obtained in this study are in 
accordance with the literature which refers E. coli as the prevalent species causing 
UTI. During two years, Correia, Costa et al. (2007) studied the etiology of urinary 
tract infections in the Centro Hospitalar do Nordeste, E.P.E. - Unidade Hospitalar 
de Bragança. In the population studied, the prevalent species isolated were E. coli, 
followed K. pneumoniae. (Correia, Costa et al. 2007) The Study for Monitoring 
Antimicrobial Resistance Trends (SMART) has been monitoring susceptibilities of 
Gram-negative pathogens, since 2009, in a study involving several hospitals 
representing the North, Center and South of Portugal. During 2009 and 2010, a 
total of 249 isolates were collected from patients diagnosed with an UTI and the 
prevalent species isolated was E. coli, representing 48.2% of the isolates, followed 
by K. pneumoniae representing 18.5% of the total isolates. (Ferreira, Diogo et al. 
2012)  
Chapter 1- Epidemiology of ESBL-producing isolates causing UTI in the elderly (2013-2014) 
41 
 
Almost the same period, Ferreira, Diaz et al. (2012) also studied the 
prevalence of pathogens causing UTIs in patients older than 65 years old 
attending the ER of the Hospital Infante D. Pedro E.P.E. Interestingly, in this case 
the prevalent species identified was K. pneumoniae followed by E. coli. However, 
more recently Magalhães, Brandão et al. (2014) reported that the percentage of  
E. coli isolates has been increasing since 2011, comparing with the percentage of 
K. pneumoniae isolates, which in 2011 was higher than E. coli but has been 
significantly decreasing in the last two years. (Ferreira, Diaz et al. 2012; 
Magalhaes, Brandao et al. 2014) 
 
 
 
 
Among E. coli and K. pneumoniae further analysis was performed regarding 
ESBL production. ESBL- producers were selected by indication of the automated 
method Vitek2® and confirmed by Etest phenotypic method. There were no 
significant discrepancies between both methods.  
Figure 10 - Number of microorganisms isolated from the samples collected, 
causing UTIs. 
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  In the last two years E. coli was the organism causing higher number of UTI, 
representing 46% of the cases both in 2013 and 2014. However, the percentage of 
K. pneumoniae ESBL-producers, 35% and 37%, was always higher than E. coli 
ESBL- producers which had a percentage of 13% in 2013 and 19% in 2014 (Table 
1). Worth noticing is the increase of ESBL- producers in both species.  
 
Table 1 - Number of isolates selected, percentage of K. pneumoniae and 
E.coli identified, and percentage of ESBL producers respectively 
Year 
 
Total number of 
clinical isolates 
 
%  
K. pneumoniae 
%  
E. coli 
% 
 K. pneumoniae 
ESBL 
%  
E. coli 
ESBL 
2013 614 18% 46% 35% 13% 
2014 649 14% 46% 37% 19% 
 
 
 
However, a study of Roxo, Magalhães et al. (2015) on the epidemiology of 
ESBL-producing isolates causing UTI in the elderly, in Aveiro, shows a reduction 
in the percentage of ESBL-producers until 2013. In 2011, 82,5% of K. pneumoniae 
isolates were ESBL-producers, and it progressively decreased until 2013. 
Nevertheless in 2014, the percentage slightly increased to 37%. E. coli          
ESBL-producers have also progressively diminished until 2013, exhibiting an 
increase (19%) in 2014. The high number of ESBL-producers in this type of 
population is disturbing and requires attention. A possible explanation is the 
constant in and out flux of elderly people living in nursing homes or their own 
house, that repeatedly visit the hospital and therefore can represent a reservoir 
and/or a vehicle of ESBL-producers. 
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3.2.3. Patients provenance and outcomes  
 
 Analyzing the data in order to conclude on the provenance of the patients 
carrying an ESBL-producer causing an UTI, it was not possible to obtain an 
accurate information in 50% of the cases due to the lack of information in the data 
base consulted. Nevertheless, it was possible to conclude that 34% of the patients 
carrying an ESBL-producer were provenant from home, whereas 17% were 
coming from nursing homes (Figure 11). Despite of the lack of information 
regarding 50% of the cases, considering the criteria used to select the isolates we 
can conclude that they are disseminated in the community. Community-acquired 
strains possessing ESBLs might be selected from the existing gastrointestinal flora 
when it is exposed to broad-spectrum antimicrobial agents. Thus, ESBL producers 
are expected to be present in general practice, but their occurrence has rarely 
been reported, probably because screening for ESBLs requires special tests and 
operator expertise. (Arpin, Dubois et al. 2003)  
 
 
Figure 11 - Provenance of the patients carrying an ESBL-producer causing 
an UTI.  
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Several studies report the difficulties in the treatment of infections caused by 
ESBL-producers. (MacVane, Tuttle et al. 2014; Cho, Jung et al. 2015; Osthoff, 
McGuinness et al. 2015). By reviewing the cases of UTIs caused by multidrug 
resistant strains, MacVane (2014) concluded that a history of recurrent UTIs, 
recent treatment with antibiotics, recent hospitalization, and previous isolation of 
an ESBL-producing microorganism, when compared with controls, were the main 
risk factors. Plus, infection-related mortality of 7.2% and 30-day UTI readmission 
were higher in ESBL positive cases than in control patients, which had around 2% 
mortality rates. (MacVane, Tuttle et al. 2014) Also, in an Australian study by 
Osthoff (2015), the length of previous stays in the hospital prior to the urine 
sampling episode, and residency in a nursing home were also found to raise the 
possibilities of having an UTI caused by ESBL positive bacteria. (Osthoff, 
McGuinness et al. 2015) In our case, and in accordance with those previous 
studies, the mortality rate was around 11% (Figure 12). This is a relatively low 
number, despite being evaluating elderly patients with infections caused by 
multiresistant bacteria. The timely detection of these strains, together with an 
appropriate initial antibiotherapy may minimize their impact on outcomes of 
patients with UTI. 
 
 
Figure 12 - Type of outcome of the patients carrying an ESBL-producer 
causing an UTI 
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3.3. General conclusion 
 
This study reveals disturbingly high numbers of ESBL-producing strains 
detected in patients over 65 years old with UTIs. Motive of especial concern is the 
fact that these samples were retrieved from outpatients, which makes this kind of 
resistance not only confined to hospital environments anymore, but already spread 
in the community. Repeatedly visiting the hospital, or living in nursing homes, turns 
these already fragile patients into potential reservoirs of these ESBL-producing 
strains.  
It becomes clear that timely use of the correct antibiotics is critical in 
minimizing the transmission and even deaths caused by ESBL-producing strains.  
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4.1. Introduction 
 
The first enzyme reported to destroy penicillin was an AmpC β-lactamase of 
Escherichia coli, in 1940, although not named AmpC yet, and the sequence of this 
gene was much later reported – in 1981. (Jacoby 2009) This kind of resistance 
mechanism can be found in Pseudomonas aeruginosa and in many 
Enterobacteriaceae species, such as Klebsiella spp., Salmonella spp., C. freundii, 
E. aerogenes, P. mirabilis, and E. coli. (Thomson 2010) According to their amino-
acid sequence, AmpC enzymes belong to class C of Ambler, whereas in the 
functional aspect, they are assigned to group 1 of Bush-Jacoby classification. 
(Marsik and Nambiar 2011)  
 
Plasmid-borne AmpC cephalosporinases were first detected in late 1980s, 
and appeared to be genetic descendants of the chromosomally encoded AmpC 
enzymes. The presence of these genes on plasmids made its transmission easier, 
and its over expression yields clinical resistance of the strains to almost all           
β-lactams: narrow and broad spectrum cephalosporins, β-lactam/ β-lactamase 
inhibitor combinations and aztreonam. (Gupta, Tak et al. 2014; Helmy and Wasfi 
2014) AmpC genes in the chromosome produce low level of β-lactamase 
expression, because they are normally repressed. But they can be de-repressed, 
induced by antimicrobials such as cefoxitin, and thus, becoming hyper expressed. 
On the other hand, AmpC genes located in plasmids constitutively express the β-
lactamase. (Marsik and Nambiar 2011) High level producers typically present 
cefoxitin-resistance. AmpC enzymes are not active against cefepime, cefpirome 
and carbapenems, thus being sensitive to those agents. Strains carrying this type 
of enzyme are therefore sensitive to cefepime (a fourth generation cephalosporin). 
But when AmpC is combined with other type of resistance mechanism, such as 
porin loss or efflux pumps, resistance levels increase significantly. (Marsik and 
Nambiar 2011) Meropenem remain the best treatment option in treating infections 
caused by this kind of pAmpC producers, even in case of co-production of ESBL 
enzymes. (Helmy and Wasfi 2014) 
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4.2. Results and discussion 
 
4.2.1. Characterization of the collected samples 
 
A total of 62 isolates were collected during the timeframe of this study, 
January 2014 to December 2014, at Centro Hospitalar do Baixo Vouga, EPE, 
Portugal. The Centro Hospitalar do Baixo Vouga, EPE, comprises three hospitalar 
units, namely Hospital Infante D. Pedro, Hospital de Águeda and Hospital 
Visconde de Salreu. The population analyzed was selected based on the 
suspicion of AmpC production given by the Vitek2® automatic system and 
confirmed by cefoxitin disc phenotypic test.  
Analyzing the distribution of the isolates by gender it was observed that 63% 
of the isolates were collected from samples retrieved from male patients and 37% 
were collected from samples retrieved from female patients (Figure 13).  
 
 
Figure 13 – Distribution of AmpC positive samples by gender; M – male,       
F – female. 
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Assuming that these results reflect the distribution and characterization of the 
AmpC-producers isolated from patients using the Centro Hospitalar do Baixo 
Vouga, E.P.E., it can be concluded that AmpC-producers are more common 
among male patients rather than female. Interestingly, in a study from (Brandão 
2013), were phenotypic methods to detect AmpC-producing Enterobacteriaceae 
were evaluated, in the same hospital, reports that this type of isolates were more 
common in women. The authors justify the results obtained due to the fact of the 
majority of the isolates had been collected from a sample urine retrieved from 
patients diagnosed with an UTI, which is known to be more common in women 
rather than men, due their anatomic differences. (Brandão 2013) In the present 
study 52% of the isolates were also isolated from samples collected from urine, 
however in this case most of them were retrieved from men. The remain isolates 
were isolated from pus samples, 35% and 10% were distributed among other 
kinds of sample, such as sputum, blood or catheter tips (Figure 14). 
 
 
 
Figure 14 - Type of sample from which AmpC positive isolates were isolated. 
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Worth noticing the percentage of isolates collected from pus samples. 
Despite MRSA being the major infection agent causing skin and soft tissue 
infections occurring in diabetics and in elderly, and thus making these infections 
difficult to treat, the presence of AmpC-producers makes the scenario even worse, 
limiting therapeutic choices. Considering the provenance of the patients, they were 
classified as inpatients and outpatients, if they were staying in the hospital or if 
they were only attending the ER at the moment of the sample collection, 
respectively. From a total of 62 isolates, 60% were isolated from samples collected 
from inpatients in different services at CHBV, while 40% were isolated from 
samples from patients attending to the ER (Figure 15).  
 
 
Figure 15 - Distribution of the isolates considering if they were collected from 
inpatients or outpatients. 
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 According to the results obtained by (Brandão 2013) it is possible to conclude 
that there is a shift in the distribution of these type of isolates in the population 
served by CHBV, since in their study AmpC-producers were more prevalent in 
outpatients. Nevertheless, the results obtained in the present study show a 
considerable high prevalence of this kind of resistance spread in the community, 
which can be explained by the difficulties in detecting AmpC enzymes, as well as 
wrong therapeutical treatment, leading them to have successfully spread 
throughout the community. (Maraskolhe, Deotale et al. 2014) 
 
4.2.2. Characterization of the AmpC-producing isolates  
 
Among the 62 isolates recovered, the automatic system VITEK2® identified 
50% of the isolates belonging to Morganella morgannii species followed by E. coli, 
29% and E. aerogenes, 13%, being those the more representative species  
(Figure 16).  
 
Figure 16 - Distribution of different causing agents among all isolates tested 
positive for AmpC expression 
Epidemiology of β-lactamase producing isolates 
54 
 
 
Portuguese and Indian studies report E. coli and K. pneumoniae as the more 
frequent species as AmpC-producers (Manageiro, Ferreira et al. 2010; 
Maraskolhe, Deotale et al. 2014), however that was not the case in the present 
study. Morganella morgannii was the most frequent species. In fact, its percentage 
was higher than expected, since the most common biological product studied was 
urine and M. morgannii species is not the most common pathogen reported to 
cause urinary tract infections. In fact, the majority of M. morgannii isolates were 
found to be recovered from pus samples. The results obtained are in accordance 
with those obtained by Brandão (2013) in the same hospital, were despite M. 
morgannii species was not the most prevalent, it was already the second more 
represented species.  (Brandão 2013) 
 
AmpC detection is supposable unnecessary in organisms that produce 
inducible chromosomal AmpC, being the species identification the only one 
needed to make it indicative – E. cloacae, E. aerogenes, C. freundii,                     
S. marcescens, Providencia sp., Morganella morgannii, Hafnia alvei, Aeromonas 
sp., and P. aeruginosa. The results obtained in the present study are worrisome 
since the species isolated are reported to possess an inducible chromosomal 
AmpC and these microorganisms have the ability to develop resistance during 
antimicrobial therapy. (Thomson 2010) Also, reports of multiple β-lactamases in a 
single pathogen, generally leading to AmpC masking the effect of ESBLs, are 
increasing. These facts improve the possibility of mistakenly reporting them as 
ESBL negative and thus being wrongly medicated. Organisms producing high 
levels of AmpC will typically give a positive ESBL screening, but will not show the 
typical increased sensitivity with clavulanic acid. (Jacoby 2009) 
 
In the present study, the carriage of an AmpC alone and both an AmpC and 
an ESBL was analyzed. Fifty two per cent of the isolates carried an AmpC alone, 
followed by 45% of isolates carrying a combination of an AmpC with an ESBL 
(Figure 17). A study of (Rawat, Singhai et al. 2013) showed ESBL production was 
seen in 39% isolates (43.7% of isolates of Enterobacteriaceae and 34% isolates 
Chapter 2-  Epidemiology of AmpC-producing Enterobacteriaceae             
  55  
 
Pseudomonas spp.). Among Enterobacteriaceae, 18.7% were pure ESBL and 
25% were ESBL and AmpC co-producers. (Rawat, Singhai et al. 2013) Another 
report from Singh, Shahid et al. (2011) shows that out of 49 ESBL positive 
isolates, co-existence of other bla genes with blaampC was present in 57.1% (28/49) 
isolates of Enterobacteriaceae. (Singh, Shahid et al. 2011) 
 
 
 
Figure 17 - Distribution of combined resistance mechanisms among AmpC 
positive strains. 
 
Accurate data on AmpC testing should be possible, although they are less 
common than ESBLs, because they have been associated with false 
cephalosporin, and sometimes falsely reported as ESBL negative. (Thomson 
2010) However, these isolates exhibited a multidrug resistance phenotype, 
therefore these findings highlight the importance of routine detection of these 
mechanisms. The majority of pAmpC producers is not susceptible to multiple 
antimicrobial substances including β-lactamase inhibitors such as clavulanic acid, 
in contrary to ESBL producers. The susceptibilities for cefepime and carbapenems 
are usually not affected by pAmpC β-lactamases. (Conen, Frei et al. 2015) The 
combination of the automated method with the cefoxitin disc seemed to be a 
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reliable choice for this detection (Figure 18). The use of the Etest strips for the 
detection of AmpC was misleading since a high number of undetermined results 
were obtained. These findings highlight the importance of routine detection of 
these mechanisms. 
 
 
Figure 18 - Muller-Hinton agar (BioMérieux, France) showing an E-test 
combined with cefoxitin disc for the detection of AmpC. 
 
 
Exception made to non-lactose fermenting Gram-negative bacteria 
intrinsically resistant to cephamicins, resistance to cefoxitin is suggestive of an 
AmpC enzyme. But it is not clear and specific, since other strains can express this 
resistance: carbapenemase producers some class A β-lactamases and decreased 
levels of outer membrane porin production (in K. pneumonia and E. coli). (Jacoby 
2009) pAmpC are known to exist in various species lacking inducible 
chromosomal AmpC (cAmpC) genes including Klebsiella spp., Proteus mirabilis, 
Salmonella enterica and Shigella spp.  
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Some authors report that empiric antimicrobial therapy was inappropriate in 
more than 30% of the cases of an infection caused by a pathogen identified to be 
an AmpC-producer. Therefore, rapid identification of pAmpC carriers is needed 
and new microbiological methods are required to simplify rapid and reliable 
detection of pAmpC carriers. (Conen, Frei et al. 2015) According to the results 
obtained, in the present study, 71% of the patients carrying an isolate identified as 
an AmpC-producer were discharged. Nevertheless, in 24% of the patients the 
outcome was death (Figure 19).  
 
 
 
Figure 19 - Outcome of the patients carrying an isolate identified as an  
AmpC- producer. 
 
 
 
Multidrug resistance is becoming a major problem observed in patients 
coming to the hospital, since it highlights the lack of control in dominating its 
spread throughout the community. From the AmpC positive diagnosed patients, 
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24% have died after visiting the hospital, presumably of the infection caused by 
the multidrug resistant bacteria. 
 
 
Most patients carrying isolates identified as AmpC-producers suffer from co-
morbidities (diabetes mellitus, chronic renal failure, abdomino-biliary diseases and 
neoplasia) and have undergone invasive procedures, such as insertion of urinary 
catheters (UC) or nasogastric tubes (NGT) or are mechanically ventilated, but both 
nosocomial- and community-related transmissions have been documented. 
Plasmid-mediated β-lactamases might spread by a horizontal gene transfer. 
(Conen, Frei et al. 2015) 
  
 
4.3. General conclusion 
 
Although AmpC-positive strains are less common than ESBL producers, its 
expression generally masks the presence of ESBLs, thus improving the probability 
of falsely reporting them as ESBL-negative. Consequently, the patient will not 
receive the appropriate medication and will possibly become the focus of new 
multiresistant strains, selected by wrong antibiotic administration.  
Plus, this study identified a large number of strains carrying two types of 
resistance – both ESBL and AmpC – fact that enhances the need to use a 
combination of methods that reliably detects both mechanisms. Cefoxitin disc 
should be used along with the automated method, since it is consistently capable 
of differentiating these kinds of resistance mechanisms.  
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5.1 Epidemiology of ESBL producing isolates causing UTI in elderly (2013 – 
2014) 
 
In the present study, the percentage of isolates producing an ESBL is still 
high, being a motive of concern and it is necessary to adopt strict policies for the 
control of antibiotics administration in order to stop the spread of these isolates. As 
measure of control of ESBL-producers, some authors emphasize the need for 
culture of a mid-stream urine specimen prior to commencing antibacterials, 
especially in patients with the risk factors identified herein associated with ESBL-
producers UTI/bacteriuria. (Osthoff, McGuinness et al. 2015)   
 
The appearance of extended-spectrum β-lactamase (ESBL)-producing 
Gram-negative bacteria causing community-acquired infections, including urinary 
tract infection, constitutes an important therapeutic challenge in choosing empirical 
antibiotics. (Cho, Jung et al. 2015; Osthoff, McGuinness et al. 2015) 
Antibiotherapy is also the reason for the emergence of resistance. Some studies 
have proven that patients with bacteremia caused by Enterobacter spp and treated 
with broad spectrum cephalosporins developed decreased susceptibility and 
augmented β-lactamase production after being treated with cefotaxime, 
ceftazidime or ceftizoxime. (Jacoby 2009)  
 
Moreover, UTI caused by ESBL-producers is associated with significant 
clinical and economic burden. The cost of care and length of stay of patients 
carrying an ESBL-producer causing an UTI can be 1.5 to 1.7 times those caused 
by non-ESBL-producers. (Lee, Kotapati et al. 2006; MacVane, Tuttle et al. 2014)  
The cost of non-urinary tract infections caused by ESBL-EK was 1.7 times the cost 
of non-urinary tract infections caused by non-ESBL producers. Prompt recognition 
and appropriate antimicrobial selection may minimize this ESBL-related impact on 
hospital costs. 
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5.2 Epidemiology of AmpC producing isolates, in CHBV 
 
AmpC β-lactamases are a major concern and clinically significant, since they 
confer resistance to cephalothin, cefazolin, cefoxitin, most penicilins and β-
lactam/β-lactamase inhibitor combinations. Inhibitors such as clavulanic acid, 
sulbactam and tazobactam have low effect on AmpC β-lactamases. In fact, they 
can induce their expression. Cloxacillin, oxacillin and aztreonam are good 
inhibitors. (Jacoby 2009; Seral, Gude et al. 2012)  
 
The laboratory detection of AmpCs can be complex and sometimes 
misleading. Also, pAmpC producers are difficult to identify by means of the 
routinely performed microbiological analyses and may be misclassified as ESBL 
producers and vice versa. (Robberts, Kohner et al. 2009; Munier, Johnson et al. 
2010) Therefore, underreporting is likely. (Perez-Perez and Hanson 2002; 
Philippon, Arlet et al. 2002; Robberts, Kohner et al. 2009) 
 
For pAmpC-related infections, data are lacking or include only small patient 
numbers. (Conen, Frei et al. 2015) Detection of AmpC β-lactamase in Klebsiella 
spp, Salmonella spp, C. koseri or P. Mirabilis is confirmatory of plasmid mediated 
AmpC production, because these organisms don’t have a chromosomal AmpC β-
lactamase. E. coli routinely carries cAmpC genes, which are very rarely hyper 
expressed, and therefore, E. coli commonly responds to second and third 
generation cephalosporins. (Conen, Frei et al. 2015) In E. coli, phenotypical 
detection of AmpC does not differentiate between chromosomal or plasmid-
mediated enzymes: lack of multiple drug resistance is suggestive of a 
chromosomal AmpC, and multiple drug resistance is consistent either 
chromosomal or plasmid-mediated AmpC production. (Thomson 2010) 
 
 It is critical that ESBL, AmpC and carbapenemases are promptly identified, 
and this can only be achieved in a time consuming, extended confirmatory 
process. Microbiology labs are obviously being optimized by maximizing automatic 
systems, dangerously disregarding of personal interpretation. This approach 
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misleads the emerging complex antimicrobial profiles, which requires expert staff 
and additional methods.  
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 6. Conclusion 
  
The results that are included in this thesis are of utmost importance, since 
they constitute a study carried out to analyze the epidemiology of β-lactamases in 
both the hospital environment and in the community. Therefore, this study 
provides a realistic panorama of the dissemination of β-lactamases in our region. 
Additionally, this study helps to highlight the importance of β-lactamases screening 
in order to prevent treatment failure.  
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8.1. Appendix 1 
 
Abstract (online publication) 
 
Epidemiology of ESBL-producing isolates causing UTI in the elderly 
(Aveiro, Portugal) 
 
I. Roxo1, S. Magalhaes1, E. Ramalheira1, S. Ferreira1,2 
1Centro Hospitalar do Baixo Vouga- EPE, Aveiro, Portugal 
2Instituto de Educação e Cidadania, Aveiro, Portugal 
 
Objectives: The world population is getting older and therefore more prone 
to acquire infections. Urinary tract infections (UTIs) are one of the most prevalent 
community-acquired infections. The aim of this study was to access the 
prevalence of ESBL-producing isolates collected from urine of elderly attending 
the Emergency Room (ER) during a 4 years period (2011-2014). 
 
Methods: The bacterial strains were isolated from urine from patients, with 
primary diagnose UTI, older than 65 years, in ER during the period between 2011 
and 2014. The Vitek2 system (according to CLSI 2012/EUCAST 2014guidelines) 
and Advanced Expert System (VITEK 2 AES) (BioMérieux, Marcy L´Étoile, 
France) were used to identify the isolates and to perform the antibiotic 
susceptibility profile of the isolates. ESBL production was confirmed using the 
Etest® (AB Biodisk) method, according to the manufacturer instructions. 
 
Results: During the timeframe studied 1686 urine samples were collected 
following the criteria listed above. The percentage of Escherichia coli isolates has 
been increasing since 2011, comparing with the percentage of Klebsiella 
pneumoniae isolates, which in 2011 was higher than E. coli but has been 
significantly decreasing in the last three years (Table 1). Table 1, also shows a 
reduction in the percentage of ESBL-producers until 2013, however in 2014 the 
percentage increased. In 2011, 82,5% of K. pneumoniae isolates were ESBL-
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producers, and progressively decreases until 2013. However in 2014, the 
percentage slightly increases to 44,1%. E. coli ESBL-producers have also 
progressively diminished until 2013, exhibiting an increase (18,0%) in 2014. 
 
Conclusions: In the last three years E. coli was the organism causing higher 
number of UTI. However, the percentage of K. pneumonia ESBL-producers was 
always higher than E. coli. Considering the criteria used to select the isolates we 
can conclude that they are disseminated in community, mainly in nursing homes, 
but also in patients who attend the ER repeatedly. Despite the percentage of 
ESBL producers has been significantly reduced in the last three years, the values 
are still high, being a motive of concern specially considering the elderly 
population. 
 
Table. 1 Number of isolates selected, percentage of K. pneumoniae and E.coli 
identified, and percentage of ESBL producers respectively. 
 
 
Clinical Isolates 
Selected 
% 
K. pneumoniae 
% 
E. coli 
% 
K. pneumoniae 
ESBL 
% 
E. coli 
ESBL 
2011 272 35.7 29.8 82.5 44.4 
2012 384 19.0 48.4 60.4 15.6 
2013 506 18.4 45.7 38.7 12.1 
2014 524 15.1 46.8 44.1 18.0 
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8.2. Appendix 2 
 
Abstract (online publication) 
 
Surveillance of MDR Gram-negatives ESBL-producers and carbapenem 
resistant, in 12 years period (2003-2014) in Aveiro, Portugal 
I. Roxo1, S. Magalhaes1, E. Ramalheira1, S. Ferreira2 
 
1Centro Hospitalar do Baixo Vouga- EPE, Aveiro, Portugal 
2Instituto de Educação e Cidadania, Aveiro, Portugal 
 
Objectives: Multidrug resistance has become a burden to the health care 
system.  The present study was undertaken to determine the prevalence of 
multidrug resistant Gram-negatives (fermenters ESBL-producers and non-
fermenters carbapenem resistant) in a 12 years timeframe, in Centro Hospitalar do 
Baixo Vouga (CHBV), Aveiro, Portugal.  
 
Methods: During the timeframe studied, consecutive, non-duplicate bacterial 
pathogens were isolated from various clinical specimens, from inpatients and 
outpatients and exhibiting resistance to at least three different classes of 
antibiotics. Four prevalent species were selected, namely Escherichia coli (EC), 
Klebsiella pneumoniae (KP), Pseudomonas aeruginosa (PA) and Acinetobacter 
baumannii (AB). Identification of the isolates was performed with the Vitek2 
system and Advanced Expert System (VITEK 2 AES) (BioMérieux, Marcy L´Étoile, 
France). Antimicrobial susceptibility profile to >20 antimicrobial agents was 
evaluated according to CLSI 2012/EUCAST 2014 guidelines. ESBL producers 
were confirmed by Etest (AB Biodisk) ESBL with cefotaxime/cefotaxime + 
clavulanic acid and ceftazidime/ceftazidime + clavulanic acid strips, according to 
manufacturer’s instructions.  
 
Results: 14209 isolates were included in this study, according to the criteria 
listed above. 11109 were fermenters, 8639 belong to EC species and 2425 belong 
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to KP species. Among these, a total of 11% (1549) isolates were ESBL producers. 
An ESBL phenotype was detected in 36% (869/2425) of the KP and 8% 
(680/8639) of the EC. Comparing both species, the number of KP ESBL-producers 
was most of the time higher than EC ESBL-producers. 3100 were non-fermenters, 
2446 belong to PA species and 654 belong to AB species. It was observed an 
increase of resistance rates to carbapenems: meropenem and imipenem. 
Resistance to colistin on the other hand did not show significative variation. 
 
Conclusion:  KP isolates are a major concern since despite the total number 
being inferior to E. coli, the number of ESBL-producers belonging to that species is 
higher.  The number of ESBL-producing isolates of these species has been 
significantly increasing in the last 12 years and requires surveillance.  The 
increase of carbapenem resistance exhibited, in the last 5 years by the non- 
fermenters, was extremely high and compromises the use of these antibiotics to 
treat infections caused by these pathogens. This fact can be explained by the 
presence of an integron carrying a VIM gene, among the PA isolates in our 
hospital. Also, long-term dissemination of a blaOXA-40 producer A. baumannii in 
the Iberian Peninsula has been reported by da Silva and co-workers, thus 
unsurprisingly it was detected in our hospital. However, this limits the therapeutic 
options available, thus becoming a cause for concern. Colistin remains the most 
active drug against both PA and AB in the isolates collected in CHBV. 
 
 
